Loading stock data…
Zenas BioPharma (ZBIO)
$33.39+0.51 (+1.55%)
Market OpenUpdated 9:59 AM EDT
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zenas BioPharma, Inc. in the Healthcare sector is trading at $33.39 with a market capitalization of $1.1B. Wall Street consensus targets $47.00 (8 analysts), implying a +40.8% move over the next 12 months. The stock is currently 25% below its 52-week high of $44.60, remaining 28.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +40.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0↓ | $10.00M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$77.35M↓ | -$71.31M↓ | -$47.58M↑ | -$55.16M↓ | -$37.33M |
| Net Income | -$80.99M↑ | -$240.44M↓ | -$51.50M↑ | -$52.22M↓ | -$33.57M |
Peer Comparison
JNJUNHPFE
Fundamentals
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.13B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-126.60%
Volume
Today's trading volume
33,138
Recent News
Fortune Brands and 4 More Stocks See Action From Activist Investors
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says
Zenas BioPharma (ZBIO) remains undervalued, as investor concerns over its phase 3 INDIGO trial for o
Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential
Zenas BioPharma Inc. (NASDAQ:ZBIO) is one of the best IPO stocks with huge upside potential. On June 2, Zenas announced positive results from the Phase 3 INDIGO trial of obexelimab for Immunoglobulin G4-Related Disease. The study met its primary and all key secondary endpoints, demonstrating a 56% reduction in flare risk compared to placebo and […]
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
This clinical-stage biotech focused on immunology therapies reported a notable insider buy amid a year of strong stock performance.
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Amid Fresh Economic Signals
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively tr